Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#4060
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$71.45
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-4.13%
Change (1 year)
100.42%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
P/S ratio for Dianthus Therapeutics, Inc. (DNTH)
P/S ratio as of October 2026 TTM: 2.20K
According to Dianthus Therapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.20K. At the end of 2023 the company had a P/S ratio of 18.97.
P/S ratio history for Dianthus Therapeutics, Inc. from 2016 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
